Catherine G. Lam

Catherine G. Lam

Auto-generated profile, based on publicly available information

Catherine G. Lam

Department of Global Pediatric Medicine St. Jude Children's Research Hospital Memphis Tennessee USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2019 in Science
Verified
Journal Article
Closed access
PDF file
CLCatherine G. Lam
Catherine G. Lam
SHScott C. Howard
Scott C. Howard
EBEric Bouffet
Eric Bouffet
KPKathy Pritchard-Jones
Kathy Pritchard-Jones
Each year ~429,000 children and adolescents aged 0 to 19 years are expected to develop cancer. Five-year survival rates exceed 80% for the 45,000 children with cancer in high-income countries (HICs) but are less than 30% for the 384,000 children in lower-middle-income countries (LMICs). Improved survival rates in HICs have been achieved through multidisciplinary care and research, with treatment regimens using mostly generic medicines and optimized risk stratification. Children’s outcomes in LMICs can be improved through global collaborative partnerships that help local leaders adapt effective treatments to local resources and clinical needs, as well as address common problems such as delayed diagnosis and treatment abandonment. Together, these approaches may bring within reach the global survival target recently set by the World Health Organization: 60% survival for all children with cancer by 2030.

1 June 2000 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
KCKyle N. Cowan
Kyle N. Cowan
AHAdrian Heilbut
Adrian Heilbut
THTilman Humpl
Tilman Humpl
CLCatherine Lam
Catherine Lam
SIShinya Ito
Shinya Ito
MRMarlene Rabinovitch
Marlene Rabinovitch

1 August 2011 in The Lancet Oncology
Verified
Journal Article
Closed access
SMSaskia Mostert
Saskia Mostert
RARamandeep Singh Arora
Ramandeep Singh Arora
MAMagda Arreola
Magda Arreola
PBPoonam Bagai
Poonam Bagai
PFPaola Friedrich
Paola Friedrich
RRRaul C Ribeiro
Raul C Ribeiro

1 May 2018 in The Lancet Oncology
Verified
Journal Article
Closed access
SHScott C Howard
Scott C Howard
AZAlia Zaidi
Alia Zaidi
XCXueyuan Cao
Xueyuan Cao
OWOlivier Weil
Olivier Weil
PBPierre Bey
Pierre Bey
AGAnne Gagnepain-Lacheteau
Anne Gagnepain-Lacheteau

13 October 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PFPaola Friedrich
Paola Friedrich
CLCatherine G Lam
Catherine G Lam
GKGeetinder Kaur
Geetinder Kaur
EIElena Itriago
Elena Itriago
RRRaul C Ribeiro
Raul C Ribeiro
RARamandeep S Arora
Ramandeep S Arora
Understanding and addressing treatment abandonment (TxA) is crucial for bridging the pediatric cancer survival gap between high-income (HIC) and low-and middle-income countries (LMC). In childhood cancer, TxA is defined as failure to start or complete curative cancer therapy and known to be a complex phenomenon. With rising interest on causes and consequences of TxA in LMC, this study aimed to establish the lay-of-the-land regarding determinants of TxA globally, perform and promote comparative research, and raise awareness on this subject. Physicians (medical oncologists, surgeons, and radiation therapists), nurses, social workers, and psychologists involved in care of children with cancer were approached through an online survey February-May 2012. Queries addressed social, economic, and treatment-related determinants of TxA. Free-text comments were collected. Descriptive and qualitative analyses were performed. Appraisal of overall frequency, burden, and predictors of TxA has been reported separately. 581 responses from 101 countries were obtained (contact rate = 26%, cooperation rate = 70%). Most respondents were physicians (86%), practicing pediatric hematology/oncology (86%) for >10 years (54%). Providers from LMC considered social/economic factors (families’ low socioeconomic status, low education, and long travel time), as most influential in increasing risk of TxA. Treatment-related considerations such as preference for complementary and alternative medicine and concerns about treatment adverse effects and toxicity, were perceived to play an important role in both LMC and HIC. Perceived prognosis seemed to mediate the role of other determinants such as diagnosis and treatment phase on TxA risk. For example, high-risk of TxA was most frequently reported when prognosis clearly worsened (i.e. lack of response to therapy, relapse), or conversely when the patient appeared improved (i.e. induction completed, mass removed), as well as before aggressive/mutilating surgery. Provider responses allowed development of an expanded conceptual model of determinants of TxA; one which illustrates established and emerging individual, family, center, and context specific factors to be considered in order to tackle this problem. Emerging factors included vulnerability, family dynamics, perceptions, center capacity, public awareness, and governmental healthcare financing, among others. TxA is a complex and multifactorial phenomenon. With increased recognition of the role of TxA on global pediatric cancer outcomes, factors beyond social/economic status and beliefs have emerged. Our results provide insights regarding the role of established determinants of TxA in different geographical and economic contexts, allow probing of key determinants by deliberating their mechanisms, and allow building an expanded conceptual model of established and emerging determinants TxA.

30 September 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PFPaola Friedrich
Paola Friedrich
CLCatherine G. Lam
Catherine G. Lam
EIElena Itriago
Elena Itriago
RPRafael Perez
Rafael Perez
RRRaul C. Ribeiro
Raul C. Ribeiro
RARamandeep S. Arora
Ramandeep S. Arora
Treatment abandonment (TxA) is recognized as a leading cause of treatment failure for children with cancer in low-and-middle-income countries (LMC). However, its global frequency and burden have remained elusive due to lack of global data. This study aimed to obtain an estimate using survey and population data. Childhood cancer clinicians (medical oncologists, surgeons, and radiation therapists), nurses, social workers, and psychologists involved in care of children with cancer were approached through an online survey February-May 2012. Incidence and population data were obtained from public sources. Descriptive, univariable, and multivariable analyses were conducted. 602 responses from 101 countries were obtained from physicians (84%), practicing pediatric hematology/oncology (83%) in general or children’s hospitals (79%). Results suggested, 23,854 (15%) of 155,088 children <15 years old newly diagnosed with cancer annually in the countries analyzed, abandon therapy. Importantly, 83% of new childhood cancer cases and 99% of TxA were attributable to LMC. The annual number of cases of TxA expected in LMC worldwide (26,166) was nearly equivalent to the annual number of cancer cases in children <15 years expected in HIC (26,368). Approximately two thirds of LMC had median TxA≥6%, but TxA ≥6% was reported in high- (9%), upper-middle- (41%), lower-middle- (80%), and low-income countries (90%, p6% were outside the capital. Lower national income category, higher reliance on out-of-pocket payments, and high prevalence of economic hardship at the center were independent contextual predictors for TxA ≥6% (p<0.001). Global survival data available for more developed and less developed regions suggests TxA may account for at least a third of the survival gap between HIC and LMC. Results show TxA is prevalent (compromising cancer survival for 1 in 7 children globally), confirm the suspected high burden of TxA in LMC, and illustrate the negative impact of poverty on its occurrence. The present estimates may appear small compared to the global burden of child death from malnutrition and infection (measured in millions). However, absolute numbers suggest the burden of TxA in LMC is nearly equivalent to annually losing all kids diagnosed with cancer in HIC just to TxA, without even considering deaths from disease progression, relapse or toxicity–the main causes of childhood cancer mortality in HIC. Results document the importance of monitoring and addressing TxA as part of childhood cancer outcomes in at-risk settings.